Clinical Trials Logo

Retinoblastoma clinical trials

View clinical trials related to Retinoblastoma.

Filter by:

NCT ID: NCT06227962 Enrolling by invitation - Retinoblastoma Clinical Trials

Cognitive Functioning and Health Related Quality of Life in Retinoblastoma Survivors

RbNeuroQoL
Start date: October 26, 2023
Phase:
Study type: Observational

A retrospective crosssectional observational study of the effects of oncological treatment and frequent general anesthesia on neuropsychological development, psychosocial functioning (in terms of anxiety, depression, peer relations, perceived cognitive functioning and potential trauma) and health related quality of life in children and young adults who were treated or screened for retinoblastoma.

NCT ID: NCT05687474 Recruiting - Cystic Fibrosis Clinical Trials

Baby Detect : Genomic Newborn Screening

Start date: September 1, 2022
Phase:
Study type: Observational

Newborn screening (NBS) is a global initiative of systematic testing at birth to identify babies with pre-defined severe but treatable conditions. With a simple blood test, rare genetic conditions can be easily detected, and the early start of transformative treatment will help avoid severe disabilities and increase the quality of life. Baby Detect Project is an innovative NBS program using a panel of target sequencing that aims to identify 126 treatable severe early onset genetic diseases at birth caused by 361 genes. The list of diseases has been established in close collaboration with the Paediatricians of the University Hospital in Liege. The investigators use dedicated dried blood spots collected between the first day and 28 days of life of babies, after a consent sign by parents.

NCT ID: NCT05655598 Recruiting - Bladder Cancer Clinical Trials

TAS-116 Plus Palbociclib in Breast and Rb-null Cancer

Start date: September 12, 2023
Phase: Phase 1
Study type: Interventional

The purpose of this study is to evaluate the safety and efficacy of TAS-116 with palbociclib in two groups of patients: - Patients with advanced breast cancer that has become worse after taking palbociclib alone - Patients with cancers that have an abnormality in a gene called the "retinoblastoma gene".

NCT ID: NCT05504291 Recruiting - Clinical trials for Unilateral Retinoblastoma

A Study to Give Treatment Inside the Eye to Treat Retinoblastoma

Start date: November 4, 2022
Phase: Phase 2
Study type: Interventional

This phase II trial tests the safety and side effects of adding melphalan (by injecting it into the eye) to standard chemotherapy in early treatment of patients with retinoblastoma (RB). RB is a type of cancer that forms in the tissues of the retina (the light-sensitive layers of nerve tissue at the back of the eye). It may be hereditary or nonhereditary (sporadic). RB is considered harder to treat (higher risk) when there are vitreous seeds present. Vitreous seeds are RB tumors in the jelly-like fluid of the eye (called the vitreous humor). The term, risk, refers to the chance of the cancer not responding to treatment or coming back after treatment. Melphalan is in a class of medications called alkylating agents. It may kill cancer cells by damaging their deoxyribonucleic acid (DNA) and stopping them from dividing. Other chemotherapy drugs given during this trial include carboplatin, vincristine, and etoposide. Carboplatin is in a class of medications known as platinum-containing compounds. It works in a way similar to the anticancer drug cisplatin, but may be better tolerated than cisplatin. Carboplatin works by killing, stopping or slowing the growth of cancer cells. Vincristine is in a class of medications called vinca alkaloids. It works by stopping cancer cells from growing and dividing and may kill them. Etoposide is in a class of medications known as podophyllotoxin derivatives. It blocks a certain enzyme needed for cell division and DNA repair and may kill cancer cells. Adding melphalan to standard chemotherapy early in treatment may improve the ability to treat vitreous seeds and may be better than standard chemotherapy alone in treating retinoblastoma.

NCT ID: NCT05308043 Recruiting - Retinoblastoma Clinical Trials

Deep Learning in Retinoblastoma Detection and Monitoring.

Start date: March 1, 2020
Phase:
Study type: Observational

Retinoblastoma is the most common eye cancer of childhood. Eye-preserving therapies require routine monitoring of retinoblastoma regression and recurrence to guide corresponding treatment. In the current study, we develop a deep learning algorism that can simultaneously identify retinoblastoma tumours on Retcam images and distinguish between active and inactive retinoblastoma tumours. This algorism will be validated through a prospectively collected dataset.

NCT ID: NCT05080010 Recruiting - Retinoblastoma Clinical Trials

Adjuvant Chemotherapy for High-risk Postenucleation Retinoblastoma

Start date: November 1, 2020
Phase: Phase 3
Study type: Interventional

The purpose of this study is to determine the effect of 3 cycles of chemotherapy(CEV) in the treatment of Stage I enucleated retinoblastoma.

NCT ID: NCT05028270 Not yet recruiting - Retinoblastoma Clinical Trials

Treatment of Intraocular Retinoblastoma

Start date: June 20, 2022
Phase:
Study type: Observational

This study compares the effects of balloon technology and microcatheter technology on the eye protection rate of neuroblastoma

NCT ID: NCT04990271 Recruiting - Retinoblastoma Clinical Trials

A Clinical Study on the Efficacy and Safety of VEC Intravenous Chemotherapy Combined With Conbercept Intravitreal Injection in the Treatment of Retinoblastoma

Start date: July 5, 2021
Phase: Phase 2
Study type: Interventional

This prospective, multi-center, open single-arm Phase II clinical trial is designed to investigate the efficacy and safety of intravenous chemotherapy combined with Conbercept intravitreal injection in the treatment of retinoblastoma.

NCT ID: NCT04959097 Recruiting - Retinoblastoma Clinical Trials

RB Liquid Biopsy Biorepository

rbliqbx
Start date: January 1, 2017
Phase:
Study type: Observational [Patient Registry]

Retinoblastoma (RB) is a primary eye cancer that forms in the back of the eye of infants and toddlers. Traditionally, RB is diagnosed without a biopsy; tumor can only be studied once an eye has been surgically removed. Given this limitation, we use aqueous humor (AH), the clear fluid in the front of the eye to detect specific markers, or information, that comes from the tumor itself.

NCT ID: NCT04903678 Recruiting - Clinical trials for Retinoblastoma, Extraocular

Intrathecal Chemotherapy for Central Nervous System Metastasis in Retinoblastoma

Start date: May 1, 2021
Phase: N/A
Study type: Interventional

Retinoblastoma is the most common intraocular malignancy in infancy and childhood. The overall survival rate of retinoblastoma was reported to exceed 95% when children were early diagnosed with localized intraocular phase. The advanced retinoblastoma cases with central nervous system metastasis (CNS)is associated with exceedingly poor prognosis. CNS metastasis is the main cause of death in retinoblastoma. Meningeal involvement combined with spinal cord membrane involvement might be due to the meninges invasion and/or the spreading of CSF. As the most sensitive drug to retinoblastoma tumor cells in vitro, melphalan is the most important drug in the local treatment of retinoblastoma, and it is also an irreplaceable drug in the current eye preservation treatment, which greatly improves the success rate of eye preservation for advanced retinoblastoma. According to the research and the practice of vitreous injection (melphalan), the drug concentration in vitreous can effectively kill retinoblastoma tumor cells. It is reasonable to speculate that the tumor cells in CSF can be effectively killed by melphalan. Therefore, based on the above background, this study will explore the effectiveness and feasibility of intrathecal injection of melphalan in patients with CNS metastasis of retinoblastoma through a multicenter prospective study.